Aviva
IONS icon

Aviva’s Ionis Pharmaceuticals IONS Stock Holding History

Aviva’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,809
Closed -$1.46M – 962
2020
Q4 		$1.46M Sell
25,809
-19,110
-43% -$952K 0.01% 776
2020
Q3 		$2.13M Buy
44,919
+6,470
+17% +$359K 0.01% 768
2020
Q2 		$2.27M Sell
38,449
-37,284
-49% -$2.07M 0.01% 732
2020
Q1 		$3.58M Buy
+75,733
New +$4.22M 0.03% 589
2019
Q3 		– Sell
-207,238
Closed -$13.3M – 801
2019
Q2 		$13.3M Sell
207,238
-327
-0.2% -$23.1K 0.09% 211
2019
Q1 		$16.8M Hold
207,565
– – 0.11% 181
2018
Q4 		$11.2M Buy
207,565
+6,588
+3% +$336K 0.08% 240
2018
Q3 		$10.4M Sell
200,977
-7,428
-4% -$349K 0.06% 319
2018
Q2 		$8.68M Sell
208,405
-4,020
-2% -$178K 0.05% 348
2018
Q1 		$9.36M Sell
212,425
-1,099
-0.5% -$55.8K 0.06% 319
2017
Q4 		$10.7M Buy
213,524
+6,740
+3% +$370K 0.06% 318
2017
Q3 		$10.5M Buy
206,784
+6,526
+3% +$342K 0.06% 336
2017
Q2 		$10.2M Buy
+200,258
New +$9.33M 0.06% 351
2014
Q3 		– Sell
-149,041
Closed -$5.13M – 843
2014
Q2 		$5.13M Buy
+149,041
New +$4.69M 0.04% 480

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aviva's IONS Position: Q1 2021 in Review

Aviva sold out of Ionis Pharmaceuticals (IONS) in Q1 2021, closing a stake of 25,809 shares — an estimated $1.46M sold.

Aviva first reported a position in IONS in Q2 2014 and held it in 14 quarters. The position peaked at $16.8M in Q1 2019. 365 funds tracked by Wall St. Rank hold IONS as of Q1 2021.

  • Aviva reported no remaining Ionis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Aviva sold 25,809 Ionis Pharmaceuticals shares in Q1 2021, an estimated $1.46M.
  • Aviva first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 14 quarters.
  • Aviva's Ionis Pharmaceuticals position peaked at $16.8M in Q1 2019.
  • 365 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2021.

Based on Aviva's 13F filing for Q1 2021, filed 13 May 2021.